| Literature DB >> 27815529 |
John J Lee1,2,3,4, Michael E Rothenberg1,5, E Scott Seeley6, Bryan Zimdahl1,2,3, Sally Kawano1,2,3, Wan-Jin Lu1,2,3, Kunyoo Shin1,2,3,7, Tomoyo Sakata-Kato8, James K Chen8, Maximilian Diehn1,9,10, Michael F Clarke1,4,10, Philip A Beachy11,2,3,10.
Abstract
Inflammation disrupts tissue architecture and function, thereby contributing to the pathogenesis of diverse diseases; the signals that promote or restrict tissue inflammation thus represent potential targets for therapeutic intervention. Here, we report that genetic or pharmacologic Hedgehog pathway inhibition intensifies colon inflammation (colitis) in mice. Conversely, genetic augmentation of Hedgehog response and systemic small-molecule Hedgehog pathway activation potently ameliorate colitis and restrain initiation and progression of colitis-induced adenocarcinoma. Within the colon, the Hedgehog protein signal does not act directly on the epithelium itself, but on underlying stromal cells to induce expression of IL-10, an immune-modulatory cytokine long known to suppress inflammatory intestinal damage. IL-10 function is required for the full protective effect of small-molecule Hedgehog pathway activation in colitis; this pharmacologic augmentation of Hedgehog pathway activity and stromal IL-10 expression are associated with increased presence of CD4+Foxp3+ regulatory T cells. We thus identify stromal cells as cellular coordinators of colon inflammation and suggest their pharmacologic manipulation as a potential means to treat colitis.Entities:
Keywords: Hedgehog signaling; colitis; colon cancer; inflammatory bowel disease; interleukin-10
Mesh:
Substances:
Year: 2016 PMID: 27815529 PMCID: PMC5127312 DOI: 10.1073/pnas.1616447113
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205